U.S. markets open in 4 hours 58 minutes

Regencell Bioscience Holdings Limited (RGC)

NasdaqCM - NasdaqCM Delayed Price. Currency in USD
29.600.00 (0.00%)
At close: 03:54PM EST

Regencell Bioscience Holdings Limited

First Commercial Building
11th Floor 33-35 Leighton Road
Causeway Bay
Hong Kong
852 2155 0823

IndustryDrug Manufacturers—Specialty & Generic
Full Time Employees13

Key Executives

NameTitlePayExercisedYear Born
Mr. Yat-Gai AuFounder, Chairman & CEON/AN/A1973
Ms. Michelle ChanFinancial ControllerN/AN/AN/A
Mr. Wai Hong ChungCOO & Chief Strategy OfficerN/AN/A1977
Mr. Tien Hsiang ChauExec. OfficerN/AN/A1970
Ms. Antonia AssangSr. VP of Project ManagementN/AN/AN/A
Amounts are as of December 31, 2022 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Regencell Bioscience Holdings Limited operates as a Traditional Chinese medicine (TCM) bioscience company. It focuses on the research, development, and commercialization of TCM for the treatment of neurocognitive disorders and degeneration, primarily attention deficit hyperactivity disorder and autism spectrum disorder. The company was incorporated in 2014 and is headquartered in Causeway Bay, Hong Kong.

Corporate Governance

Regencell Bioscience Holdings Limited’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.